- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Squamous cell anal carcinoma (SCAC)
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Retifanlimab – March 2026
Solution concentrate for I.V. infusion 500 mg in 20 mL
Last updated
11 March 2026